{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T03:58:56Z","timestamp":1778126336840,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kristina Kramer received a promotional scholarship of the Faculty of Medicine, LMU Munich, Germany. The funders did not participate in the design, evaluation, or publication of the study."},{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Metastatic prostate cancer remains a therapeutic challenge. Based on data of the STAMPEDE trial, patients with a low metastatic burden showed prolonged failure-free and overall survival when treated with prostate radio therapy (RT) in addition to standard of care (SOC). The objective of this study was to determine the cost-effectiveness of additional prostate RT compared to SOC alone for following subgroups: non-regional lymph node (NRLN) metastases, up to three bone metastases and four or more bone metastases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A partitioned survival model was implemented with clinical data from STAMPEDE trial. Analyses were performed from a United States healthcare system perspective. Costs for treatment and adverse events were derived from Medicare coverage. Utilities for health states were derived from public databases and literature. Outcome measurements included incremental costs, effectiveness, and cost-effectiveness ratio. The willingness-to-pay threshold was set to USD 100,000 per quality-adjusted life year (QALY).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Additional RT led to 0.92 incremental QALYs with increased costs of USD 26,098 with an incremental cost-effectiveness ratio (ICER) of USD 28,452\/QALY for patients with only NRLN metastases and 3.83 incremental QALYs with increased costs of USD 153,490 with an ICER of USD 40,032\/QALY for patients with up to three bone metastases. Sensitivity analysis showed robustness of the model regarding various parameters. In probabilistic sensitivity analysis using Monte Carlo simulation with 10,000 iterations, additional RT was found as the cost-effective strategy in over 96% for both subgroups iterations at a willingness-to-pay threshold of USD 100,000\/QALYs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Additional RT is cost-effective in patients with only NRLN metastases and up to three metastases compared to SOC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-024-02544-0","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T05:25:32Z","timestamp":1732166732000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness analysis of additional local prostate radio therapy in metastatic prostate cancer from a medicare perspective"],"prefix":"10.1186","volume":"19","author":[{"given":"Kristina K. M.","family":"Kramer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina-Sophie","family":"Schmidt-Hegemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thilo","family":"Westhofen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Foglar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Benedikt","family":"Westphalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang G.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Mehrens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"issue":"1","key":"2544_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"41","key":"2544_CR2","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","volume":"69","author":"DA Siegel","year":"2020","unstructured":"Siegel DA, et al. Prostate cancer incidence and survival, by stage and race\/ethnicity - United States, 2001\u20132017. MMWR Morb Mortal Wkly Rep. 2020;69(41):1473\u201380.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2544_CR3","unstructured":"Cancer Statistics Explorer Network. [cited 2023 June 25]; Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=66&data_type=1&graph_type=4&compareBy=age_range&chk_age_range_1=1&hdn_sex=2&race=1&advopt_precision=1&hdn_view=0&advopt_show_apc=on&advopt_display=2"},{"issue":"6","key":"2544_CR4","first-page":"1058","volume":"65","author":"SH Culp","year":"2014","unstructured":"Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study Eur Urol. 2014;65(6):1058\u201366.","journal-title":"A SEER-based study Eur Urol"},{"issue":"1","key":"2544_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.eururo.2014.08.056","volume":"67","author":"N Fossati","year":"2015","unstructured":"Fossati N, et al. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. Eur Urol. 2015;67(1):3\u20136.","journal-title":"Eur Urol"},{"issue":"3","key":"2544_CR6","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.eururo.2014.04.009","volume":"66","author":"C Gratzke","year":"2014","unstructured":"Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol. 2014;66(3):602\u20133.","journal-title":"Eur Urol"},{"issue":"24","key":"2544_CR7","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.2016.67.4788","volume":"34","author":"CG Rusthoven","year":"2016","unstructured":"Rusthoven CG, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol. 2016;34(24):2835\u201342.","journal-title":"J Clin Oncol"},{"issue":"10162","key":"2544_CR8","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial (article and\/or supplementary material). Lancet. 2018;392(10162):2353\u201366.","journal-title":"Lancet"},{"issue":"4","key":"2544_CR9","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamaoncol.2020.7857","volume":"7","author":"A Ali","year":"2021","unstructured":"Ali A, et al. Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2021;7(4):555\u201363.","journal-title":"JAMA Oncol"},{"issue":"1","key":"2544_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/UPJ.0000000000000363","volume":"10","author":"TA Olsen","year":"2023","unstructured":"Olsen TA, et al. The cost of metastatic prostate cancer in the United States. Urol Pract. 2023;10(1):41\u20137.","journal-title":"Urol Pract"},{"key":"2544_CR11","unstructured":"TreeAge Pro 2021, R1, TreeAge Software, Williamstown, MA. 2021."},{"issue":"1","key":"2544_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3\u20139.","journal-title":"Value Health"},{"key":"2544_CR13","unstructured":"Mitchell M, Muftakhidinov B, Winchen. Engauge Digitizer, Version 12.1, Torrance California, United States, Open Source."},{"key":"2544_CR14","unstructured":"ryandata, Survival Analysis in R, GPL-3.0 license, modified."},{"key":"2544_CR15","unstructured":"Core R, R Core Team, R. A Language and Environment for Statistical Computing, Vienna, Austria, Open Source. 2022."},{"key":"2544_CR16","unstructured":"Medicare & Medicaid Spending by Drug. [cited 2022 July 10]; Available from: https:\/\/data.cms.gov\/summary-statistics-on-use-and-payments\/medicare-medicaid-spending-by-drug"},{"key":"2544_CR17","unstructured":"Physician fee schedule search. Center for Medicare and Medicaid Services. [cited 2021 January 4]; Available from: https:\/\/www.cms.gov\/apps\/physician-fee-schedule\/search\/search-criteria.aspx."},{"issue":"5","key":"2544_CR18","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jval.2021.10.016","volume":"25","author":"L Wang","year":"2022","unstructured":"Wang L, et al. Cost-effectiveness of systemic treatments for metastatic castration-sensitive prostate cancer: an economic evaluation based on network meta-analysis. Value Health. 2022;25(5):796\u2013802.","journal-title":"Value Health"},{"key":"2544_CR19","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Version 4.2022. [cited 2022 November 18]; Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"2544_CR20","unstructured":"RADIATION ONCOLOGY CPT\u00ae and HCPCS CODES BY PROCESS OF CARE. [cited 2022 July 10]; Available from: https:\/\/www.astro.org\/uploadedFiles\/_MAIN_SITE\/Daily_Practice\/Reimbursement\/Practice_Management_Resources\/Content_Pieces\/CPTCodeChart.pdf"},{"issue":"7","key":"2544_CR21","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/cncr.29892","volume":"122","author":"C Sanyal","year":"2016","unstructured":"Sanyal C, et al. Management of localized and advanced prostate cancer in Canada: a lifetime cost and quality-adjusted life-year analysis. Cancer. 2016;122(7):1085\u201396.","journal-title":"Cancer"},{"issue":"5","key":"2544_CR22","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s11136-019-02117-9","volume":"28","author":"F Hall","year":"2019","unstructured":"Hall F, et al. Estimating utilities\/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events. Qual Life Res. 2019;28(5):1191\u20139.","journal-title":"Qual Life Res"},{"issue":"3","key":"2544_CR23","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1464-410X.2012.11597.x","volume":"111","author":"MR Cooperberg","year":"2013","unstructured":"Cooperberg MR, et al. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int. 2013;111(3):437\u201350.","journal-title":"BJU Int"},{"issue":"6","key":"2544_CR24","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.euo.2019.01.004","volume":"2","author":"NJ Sathianathen","year":"2019","unstructured":"Sathianathen NJ, et al. A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer. Eur Urol Oncol. 2019;2(6):649\u201355.","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"2544_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.33787","volume":"4","author":"NH Lester-Coll","year":"2021","unstructured":"Lester-Coll NH, et al. Cost-effectiveness of prostate radiation therapy for men with newly diagnosed low-burden metastatic prostate cancer (article and\/or supplementary material). JAMA Netw Open. 2021;4(1): e2033787.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2544_CR26","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.3390\/curroncol28040219","volume":"28","author":"N Alyamani","year":"2021","unstructured":"Alyamani N, et al. Cost-utility analysis of radiation treatment modalities for intermediate-risk prostate cancer. Curr Oncol. 2021;28(4):2385\u201398.","journal-title":"Curr Oncol"},{"issue":"1","key":"2544_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1055\/a-1502-7830","volume":"194","author":"MF Froelich","year":"2022","unstructured":"Froelich MF, et al. Cost-effectiveness analysis in radiology: methods, results and implications. Rofo. 2022;194(1):29\u201338.","journal-title":"Rofo"},{"issue":"6","key":"2544_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269192","volume":"17","author":"CS Clarke","year":"2022","unstructured":"Clarke CS, et al. Cost-utility analysis of adding abiraterone acetate plus prednisone\/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. PLoS ONE. 2022;17(6): e0269192.","journal-title":"PLoS ONE"},{"issue":"3","key":"2544_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/14737167.2021.1893167","volume":"21","author":"M Rui","year":"2021","unstructured":"Rui M, et al. Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):373\u201380.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2544_CR30","unstructured":"Medicare and Medicaid Act 1965 [cited 2023 November 18]; Available from: https:\/\/www.archives.gov\/milestone-documents\/medicare-and-medicaid-act#transcript."},{"issue":"6","key":"2544_CR31","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1097\/MOU.0000000000000675","volume":"29","author":"A Ali","year":"2019","unstructured":"Ali A, Parker CC, Clarke NW. Prostate radiotherapy in newly diagnosed metastatic prostate cancer. Curr Opin Urol. 2019;29(6):620\u20138.","journal-title":"Curr Opin Urol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-024-02544-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-024-02544-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-024-02544-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T06:03:13Z","timestamp":1732168993000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-024-02544-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2544"],"URL":"https:\/\/doi.org\/10.1186\/s13014-024-02544-0","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No new patient data was generated in this study; instead, published data was utilized. For ethics approval, see cited studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}